OptimizeRx Posts $109.4M 2025 Revenue, 2026 Gross Margins Guided to Mid-60%
OptimizeRx recorded $109.4 million in 2025 revenue with adjusted EBITA of $24.3 million, and adjusted EBITA and free cash flow more than doubled year over year. The company projects 2026 gross margins in the mid-60% range and notes contracted revenue is running 15–20% below last year due to shorter durations.
1. Q4 2025 Financial Results
OptimizeRx reported full-year 2025 revenue of $109.4 million and adjusted EBITA of $24.3 million, marking more than a twofold increase in both adjusted EBITA and free cash flow compared to the prior year, underscoring the scalability of its operating model.
2. 2026 Gross Margin Guidance and Contract Trends
The company expects 2026 gross margins in the mid-60% range after a record high in Q4 2025. Year-to-date contracted revenue is 15–20% below the previous year due to shorter contract durations and a market shift away from managed services, with normalization anticipated by mid-year.
3. AI Integration and Client Spend
AI efficiencies are enabling faster message distribution and precise physician targeting, allowing clients to reallocate budgets from content creation to commercial execution. The company views AI as an enabler that enhances its value proposition rather than a disruptive force.
4. Mid-Tier Manufacturer Growth
OptimizeRx has accelerated growth among mid-tier and smaller manufacturers by offering cost-effective commercialization support for firms lacking large marketing teams and budgets, filling a market gap and driving faster-than-expected uptake in this segment.